Literature DB >> 27596331

Pathogenic Cysteine Removal Mutations in FGFR Extracellular Domains Stabilize Receptor Dimers and Perturb the TM Dimer Structure.

Sarvenaz Sarabipour1, Kalina Hristova2.   

Abstract

Missense mutations that introduce or remove cysteine residues in receptor tyrosine kinases are believed to cause pathologies by stabilizing the active receptor tyrosine kinase dimers. However, the magnitude of this stabilizing effect has not been measured for full-length receptors. Here, we characterize the dimer stabilities of three full-length fibroblast growth factor receptor (FGFR) mutants harboring pathogenic cysteine substitutions: the C178S FGFR1 mutant, the C342R FGFR2 mutant, and the C228R FGFR3 mutant. We find that the three mutations stabilize the FGFR dimers. We further see that the mutations alter the configuration of the FGFR transmembrane dimers. Thus, both aberrant dimerization and perturbed dimer structure likely contribute to the pathological phenotypes arising due to these mutations.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  FGFR; cysteine mutation; dimer stability; disulfide bond; structural change

Mesh:

Substances:

Year:  2016        PMID: 27596331      PMCID: PMC5474753          DOI: 10.1016/j.jmb.2016.08.026

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  53 in total

1.  Clinical spectrum of fibroblast growth factor receptor mutations.

Authors:  M R Passos-Bueno; W R Wilcox; E W Jabs; A L Sertié; L G Alonso; H Kitoh
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

2.  Evidence for digenic inheritance in some cases of Antley-Bixler syndrome?

Authors:  W Reardon; A Smith; J W Honour; P Hindmarsh; D Das; G Rumsby; I Nelson; S Malcolm; L Adès; D Sillence; D Kumar; C DeLozier-Blanchet; S McKee; T Kelly; W L McKeehan; M Baraitser; R M Winter
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

3.  Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome.

Authors:  Catherine Dodé; Jacqueline Levilliers; Jean-Michel Dupont; Anne De Paepe; Nathalie Le Dû; Nadia Soussi-Yanicostas; Roney S Coimbra; Sedigheh Delmaghani; Sylvie Compain-Nouaille; Françoise Baverel; Christophe Pêcheux; Dominique Le Tessier; Corinne Cruaud; Marc Delpech; Frank Speleman; Stefan Vermeulen; Andrea Amalfitano; Yvan Bachelot; Philippe Bouchard; Sylvie Cabrol; Jean-Claude Carel; Henriette Delemarre-van de Waal; Barbara Goulet-Salmon; Marie-Laure Kottler; Odile Richard; Franco Sanchez-Franco; Robert Saura; Jacques Young; Christine Petit; Jean-Pierre Hardelin
Journal:  Nat Genet       Date:  2003-03-10       Impact factor: 38.330

4.  Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.

Authors:  Rivka Adar; Efrat Monsonego-Ornan; Pe'er David; Avner Yayon
Journal:  J Bone Miner Res       Date:  2002-05       Impact factor: 6.741

5.  The A391E mutation enhances FGFR3 activation in the absence of ligand.

Authors:  Fenghao Chen; Catherine Degnin; Melanie Laederich; William A Horton; Kalina Hristova
Journal:  Biochim Biophys Acta       Date:  2011-04-22

Review 6.  Cell signaling by receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

Review 7.  The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans.

Authors:  Z Vajo; C A Francomano; D J Wilkin
Journal:  Endocr Rev       Date:  2000-02       Impact factor: 19.871

8.  Clustering of FGFR2 gene mutations inpatients with Pfeiffer and Crouzon syndromes (FGFR2-associated craniosynostoses).

Authors:  W Kress; H Collmann; M Büsse; B Halliger-Keller; C R Mueller
Journal:  Cytogenet Cell Genet       Date:  2000

9.  Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome.

Authors:  W Reardon; R M Winter; P Rutland; L J Pulleyn; B M Jones; S Malcolm
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

10.  Description of a new mutation and characterization of FGFR1, FGFR2, and FGFR3 mutations among Brazilian patients with syndromic craniosynostoses.

Authors:  M R Passos-Bueno; A L Sertié; A Richieri-Costa; L G Alonso; M Zatz; N Alonso; D Brunoni; S F Ribeiro
Journal:  Am J Med Genet       Date:  1998-07-07
View more
  5 in total

1.  The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

Authors:  Michael D Paul; Kalina Hristova
Journal:  Chem Rev       Date:  2018-12-27       Impact factor: 60.622

2.  Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function.

Authors:  Haijiao Zhang; Sophie Means; Anna Reister Schultz; Kevin Watanabe-Smith; Bruno C Medeiros; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Tim Kükenshöner; Oliver Hantschel; Jeffrey W Tyner
Journal:  Cancer Res       Date:  2017-06-26       Impact factor: 12.701

Review 3.  The transition model of RTK activation: A quantitative framework for understanding RTK signaling and RTK modulator activity.

Authors:  Michael D Paul; Kalina Hristova
Journal:  Cytokine Growth Factor Rev       Date:  2019-11-01       Impact factor: 7.638

4.  Dimerization of the Trk receptors in the plasma membrane: effects of their cognate ligands.

Authors:  Fozia Ahmed; Kalina Hristova
Journal:  Biochem J       Date:  2018-11-30       Impact factor: 3.857

5.  FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.

Authors:  James M Cleary; Srivatsan Raghavan; Qibiao Wu; Yvonne Y Li; Liam F Spurr; Hersh V Gupta; Douglas A Rubinson; Isobel J Fetter; Jason L Hornick; Jonathan A Nowak; Giulia Siravegna; Lipika Goyal; Lei Shi; Lauren K Brais; Maureen Loftus; Atul B Shinagare; Thomas A Abrams; Thomas E Clancy; Jiping Wang; Anuj K Patel; Franck Brichory; Anne Vaslin Chessex; Ryan J Sullivan; Rachel B Keller; Sarah Denning; Emma R Hill; Geoffrey I Shapiro; Anna Pokorska-Bocci; Claudio Zanna; Kimmie Ng; Deborah Schrag; Pasi A Jänne; William C Hahn; Andrew D Cherniack; Ryan B Corcoran; Matthew Meyerson; Antoine Daina; Vincent Zoete; Nabeel Bardeesy; Brian M Wolpin
Journal:  Cancer Discov       Date:  2021-04-29       Impact factor: 39.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.